IP Verse

Nasal Powder Formulation For Treatment Of Hypoglycemia - EP3258919

The patent EP3258919 was granted to ELI Lilly on Nov 9, 2022. The application was originally filed on Feb 16, 2016 under application number EP16710352A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3258919

ELI LILLY
Application Number
EP16710352A
Filing Date
Feb 16, 2016
Status
Patent Maintained As Amended
Oct 7, 2022
Publication Date
Nov 9, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEOct 5, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (26) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2010204105
DESCRIPTIONUS2011045088
DESCRIPTIONUS2011286981
DESCRIPTIONUS2011286982
DESCRIPTIONUS2011293586
DESCRIPTIONUS2012178670
DESCRIPTIONUS2013053310
DESCRIPTIONUS2013157929
DESCRIPTIONUS2013157935
DESCRIPTIONUS2013316941
DESCRIPTIONUS2014001733
DESCRIPTIONUS2014080757
DESCRIPTIONUS5059587
DESCRIPTIONUS5702362
DESCRIPTIONUS6384016
DESCRIPTIONUS6398074
DESCRIPTIONUS6938798
DESCRIPTIONUS7722566
DESCRIPTIONWO2014004400
DESCRIPTIONWO9947160
INTERNATIONAL-SEARCH-REPORTUS2006074025
INTERNATIONAL-SEARCH-REPORTUS2011237510
INTERNATIONAL-SEARCH-REPORTWO9216196
OPPOSITIONUS2006074025
OPPOSITIONUS2011237510
OPPOSITIONWO9216196

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- A.M. ROSENFALCK et al., "Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin- dependent) diabetic patients", Diabetes Research and Clinical Practice, (19920701), vol. 17, no. 1, pages 43 - 50
OPPOSITION- anonymous, "Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults with Diabetes", Adult glucagon Protocol Version 2.0, (20130927), URL: https://s3.amazonaws.com/publicfiles.jaeb.org/t1dx/Protocols/AdultGlucagonProtocol.pdf, XP055744110
OPPOSITION- Anonymous, "History of Changes for Study: NCT01994746 Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults", Clinical trial number NCT01994746, (20150107), URL: https://clinicaltrials.gov/ct2/history/NCT01994746?V4=View#StudyPageTop, XP055744118
OPPOSITION- Bruce J. Aungst, Absorption Enhancers: Applications and Advances, The AAPS Journal, Volume 14, no 1, 2012, 10-18
OPPOSITION- C. BÖSCH et al., "Physicochemical characterization of glucagon-containing lipid micelles", Biochimica et Biophysica Acta, (19800000), pages 298 - 312
OPPOSITION- D.Z. LIU et al., "Dodecylphosphocholine-Mediated Enhancement of Paracellular Permeability and Cytotoxicity in Caco-2 Cell Monolayers", J Pharm Sci, (19991101), vol. 88, no. 11, pages 1161 - 1168
OPPOSITION- "Introduction", Michael E. Aulton, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, Elsevier Churchill Livingstone, (20070000), pages 554 - 564, XP055744172
OPPOSITION- P.H. Johnson et al, "Advances in nasal drug delivery through tight junction technology" Expert Opinion on Drug Delivery 2005, 2:2, 281-298
OPPOSITION- E. STENNINFER et al., "Intranasal glucagon treatment relieves hypoglycaemia in children with Type 1 (insulin-dependent) diabetes mellitus", Diabetologia, (19931000), vol. 36, no. 10, pages 931 - 935, XP055744125
OPPOSITION- C. BÖSCH et al., "Physicochemical characterization of glucagon-containing lipid micelles", Biochimica et Biophysica Acta, (19800000), doi:10.1016/0005-2736(80)90376-4, pages 298 - 312, XP023509139
OPPOSITION- A.M. ROSENFALCK et al., "Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin- dependent) diabetic patients", Diabetes Research and Clinical Practice, (19920701), vol. 17, no. 1, doi:10.1016/0168-8227(92)90042-P, pages 43 - 50, XP026212218
OPPOSITION- F.W.H.M. MERKUS et al., "Cyclodextrins in nasal drug delivery", Advanced Drug Delivery Reviews, (1999301), vol. 36, no. 1, doi:10.1016/S0169-409X(98)00054-4, pages 41 - 57, XP001023913
OPPOSITION- D.Z. LIU et al., "Dodecylphosphocholine-Mediated Enhancement of Paracellular Permeability and Cytotoxicity in Caco-2 Cell Monolayers", J Pharm Sci, (19991101), vol. 88, no. 11, doi:10.1021/js990094e, pages 1161 - 1168, XP001148464
OPPOSITION- M.S. QURAISHI et al., "The nasal delivery of drugs", Clin Otolaryngol, (19970800), vol. 22, no. 4, pages 289 - 301, XP055744147
OPPOSITION- T. FURUBAYASHI et al., "Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats", Biol. Pharm. Bull., (20070300), vol. 30, no. 3, pages 608 - 611, XP055744151
OPPOSITION- M.R. RICKELS et al., "Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study", Diabetes Care, (20160200), vol. 39, no. 2, pages 264 - 270, XP055744130

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents